Elranatamab 76mg/1.9ml solution for injection vials
NHS hospitals in England used £52,496,695 of indicative cost of Elranatamab 76mg/1.9ml solution for injection vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 87.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Elranatamab 76mg/1.9ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Elranatamab 76mg/1.9ml solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Imperial College Healthcare Nhs Trust | £2,121,250 |
| Nottingham University Hospitals Trust | £2,036,400 |
| The Clatterbridge Cancer Centre Nhs Ft | £2,019,430 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,960,035 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,764,880 |
| Hull And East Yorkshire Hpls Nhs Trust | £1,514,573 |
| South Tees Hosp Nhs Foundation Trust | £1,459,420 |
| Colchester Hospital University Nhs Ft | £1,455,178 |
| Barts Health Nhs Trust | £1,306,690 |
| University Hpls Of Leicester Nhs Trust | £1,298,205 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.